{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:48:23Z","timestamp":1789321703842,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["AI 111451"],"award-info":[{"award-number":["AI 111451"]}]},{"name":"National Institutes of Health","award":["AI 109925"],"award-info":[{"award-number":["AI 109925"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Seasonal influenza and the threat of global pandemics present a continuing threat to public health. However, conventional inactivated influenza vaccines (IAVs) provide little cross-protective immunity and suboptimal efficacy, even against well-matched strains. Furthermore, the protection against matched strains has been shown to be of a short duration in both mouse models and humans. M2SR (M2-deficient single-replication influenza virus) is a single-replication vaccine that has been shown to provide effective cross-protection against heterosubtypic influenza viruses in both mouse and ferret models. In the present study, we investigated the duration and mechanism of heterosubtypic protection induced by M2SR in a mouse model. We previously showed that M2SR generated from influenza A\/Puerto Rico\/8\/34 (H1N1) significantly protected C57BL\/6 mice against lethal challenge with both influenza A\/Puerto Rico\/8\/34 (H1N1, homosubtypic) and influenza A\/Aichi\/2\/1968 (H3N2, heterosubtypic), whereas the inactivated influenza vaccine provided no heterosubtypic protection. The homosubtypic protection induced by M2SR was robust and lasted for greater than 1 year, whereas that provided by the inactivated vaccine lasted for less than 6 months. The heterosubtypic protection induced by M2SR was of a somewhat shorter duration than the homosubtypic protection, with protection being evident 9 months after vaccination. However, heterosubtypic protection was not observed at 14 months post vaccination. M2SR has been shown to induce strong systemic and mucosal antibody and T cell responses. We investigated the relative importance of these immune mechanisms in heterosubtypic protection, using mice that were deficient in B cells or mice that were depleted of T cells immediately before challenge. Somewhat surprisingly, the heterosubtypic protection was completely dependent on B cells in this model, whereas the depletion of T cells had no significant effect on survival after a lethal heterosubtypic challenge. While antibody-dependent cellular cytotoxicity (ADCC) has been demonstrated to be important in the response to some influenza vaccines, a lack of Fc receptors did not affect the survival of M2SR-vaccinated mice following a lethal challenge. We examined the influenza proteins targeted by the heterosubtypic antibody response. Shortly after the H1N1 M2SR vaccination, high titers of cross-reactive antibodies to heterosubtypic H3N2 nucleoprotein (NP) and lower titers to the stalk region of the hemagglutinin (HA2) and neuraminidase (NA) proteins were observed. The high antibody titers to heterosubtypic NP persisted one year after vaccination, whereas the antibody titers to the heterosubtypic HA2 and NA proteins were very low, or below the limit of detection, at this time. These results show that the intranasal M2SR vaccine elicits durable protective immune responses against homotypic and heterosubtypic influenza infection not seen with intramuscular inactivated vaccines. Both the homo- and heterosubtypic protection induced by the single-replication vaccine are dependent on B cells in this model. While the homosubtypic protection is mediated by antibodies to the head region of HA, our data suggest that the heterosubtypic protection for M2SR is due to cross-reactive antibodies elicited against the NP, HA2, and NA antigens that are not targeted by current seasonal influenza vaccines.<\/jats:p>","DOI":"10.3390\/vaccines10122131","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T02:59:01Z","timestamp":1670900341000},"page":"2131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice"],"prefix":"10.3390","volume":"10","author":[{"given":"Sally","family":"Sarawar","sequence":"first","affiliation":[{"name":"The Biomedical Research Institute of Southern California, Oceanside, CA 92056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia R.","family":"Gabaglia","sequence":"additional","affiliation":[{"name":"The Biomedical Research Institute of Southern California, Oceanside, CA 92056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Sanchez","sequence":"additional","affiliation":[{"name":"The Biomedical Research Institute of Southern California, Oceanside, CA 92056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Hatta","sequence":"additional","affiliation":[{"name":"FluGen Inc., Madison, WI 53711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dias","sequence":"additional","affiliation":[{"name":"The Biomedical Research Institute of Southern California, Oceanside, CA 92056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Neumann","sequence":"additional","affiliation":[{"name":"Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53711, USA"},{"name":"Division of Virology, Department of Microbiology and Immunology and Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamuk","family":"Bilsel","sequence":"additional","affiliation":[{"name":"FluGen Inc., Madison, WI 53711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4049\/jimmunol.1890025","article-title":"Immunity to Influenza: Catching a Moving Target To Improve Vaccine Design","volume":"202","author":"Paules","year":"2019","journal-title":"J. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"eaan8405","DOI":"10.1126\/scitranslmed.aan8405","article-title":"Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity","volume":"10","author":"Koutsakos","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e00414-16","DOI":"10.1128\/CVI.00414-16","article-title":"Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults","volume":"24","author":"Hoft","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/jix632","article-title":"Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies","volume":"217","author":"Young","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_6","first-page":"544","article-title":"Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011\u20132012 through 2014\u201315","volume":"64","author":"Ferdinands","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20390","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: Results from the I-MOVE multicentre case-control study","volume":"18","author":"Kissling","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20389","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: Evidence of waning intra-seasonal protection","volume":"18","author":"Pebody","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_9","first-page":"20388","article-title":"Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12","volume":"18","author":"Castilla","year":"2013","journal-title":"Eurosurveillance"},{"key":"ref_10","first-page":"171","article-title":"The role of the antibody response in influenza virus infection","volume":"260","author":"Gerhard","year":"2001","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moody, M.A., Zhang, R., Walter, E.B., Woods, C.W., Ginsburg, G.S., McClain, M.T., Denny, T.N., Chen, X., Munshaw, S., and Marshall, D.J. (2011). H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025797"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"316ra192","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Eiden, J., Gordon, G., Fierro, C., Herber, R., Aitchison, R., Belshe, R., Greenberg, H., Hoft, D., Hatta, Y., and Moser, M.J. (2021). Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults. Vaccines, 9.","DOI":"10.3390\/vaccines9121388"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1016\/j.vaccine.2017.06.039","article-title":"M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza","volume":"35","author":"Hatta","year":"2017","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1016\/j.vaccine.2016.08.061","article-title":"M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice","volume":"34","author":"Sarawar","year":"2016","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1016\/j.vaccine.2018.06.053","article-title":"Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity","volume":"36","author":"Hatta","year":"2018","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/jiab374","article-title":"Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain","volume":"226","author":"Eiden","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Eiden, J., Fierro, C., Schwartz, H., Adams, M., Ellis, K.J., Aitchison, R., Herber, R., Hatta, Y., Marshall, D., and Moser, M.J. (2022). Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiac433"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1128\/JVI.00049-06","article-title":"The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly","volume":"80","author":"Horimoto","year":"2006","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.vaccine.2011.01.023","article-title":"An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus","volume":"29","author":"Hatta","year":"2011","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.96.16.9345","article-title":"Generation of influenza A viruses entirely from cloned cDNAs","volume":"96","author":"Neumann","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s007050170002","article-title":"Universal primer set for the full-length amplification of all influenza A viruses","volume":"146","author":"Hoffmann","year":"2001","journal-title":"Arch. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1128\/JVI.00450-09","article-title":"Influenza A virus lacking M2 protein as a live attenuated vaccine","volume":"83","author":"Watanabe","year":"2009","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","article-title":"FcR gamma chain deletion results in pleiotrophic effector cell defects","volume":"76","author":"Takai","year":"1994","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/rej.2006.9.117","article-title":"Antibody quality in old age","volume":"9","author":"Howard","year":"2006","journal-title":"Rejuvenation Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jmv.26241","article-title":"Antibody responses against SARS-CoV-2 in COVID-19 patients","volume":"93","author":"Liu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.4049\/jimmunol.166.12.7437","article-title":"Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells","volume":"166","author":"Benton","year":"2001","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.4049\/jimmunol.152.4.1653","article-title":"Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity","volume":"152","author":"Liang","year":"1994","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/JVI.01812-10","article-title":"T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model","volume":"85","author":"Guo","year":"2011","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1099\/vir.0.033076-0","article-title":"Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells","volume":"92","author":"Hillaire","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1086\/318084","article-title":"Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes","volume":"183","author":"Nguyen","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4049\/jimmunol.158.3.1222","article-title":"Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice","volume":"158","author":"Epstein","year":"1997","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhong, W., Liu, F., Dong, L., Lu, X., Hancock, K., Reinherz, E.L., Katz, J.M., and Sambhara, S. (2010). Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010583"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18979","DOI":"10.1073\/pnas.1013387107","article-title":"Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes","volume":"107","author":"Wang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/rmv.1713","article-title":"Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines","volume":"22","author":"Marcelin","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.1003057","article-title":"Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","author":"LaMere","year":"2011","journal-title":"J. Immunol."},{"key":"ref_43","first-page":"818","article-title":"Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed toward the Nucleoprotein","volume":"215","author":"Jegaskanda","year":"2017","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:40:13Z","timestamp":1760146813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122131"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122131","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}